Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Controlled Therapeutics receives grant from Scottish government

This article was originally published in Scrip

Executive Summary

Controlled Therapeutics (Scotland) has received a £930,000 grant from the Scottish Executive's regional selective assistance programme, which will go towards creating 23 new positions at its East Kilbride facility. The company, a subsidiary of the US firm Cytokine PharmaSciences, conducts research and manufacturing there, and Cytokine Pharmasciences' president and CEO Dennis Wilson said the company was investing $6 million in Scotland. Patent protection on its Hydrogel technology, which was acquired from the University of Strathclyde, runs out in 2012, but it plans to develop both its existing polymer technology and new technologies based on linear polymers.

You may also be interested in...



Pipeline Watch: Phase III Readouts In Liver Diseases, COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharvaris Oral HAE Candidate Heading Into Phase II In 2021

European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.

BrainStorm's Cell Therapy Disappoints In Phase III ALS Study

Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel